COMPOSITIONS AFFECTING PROGRAMMED CELL DEATH AND THEIR USE IN THE MODIFICATION OF FORESTRY PLANT DEVELOPMENT

Abstract: Novel isolated polynucleotides associated with programmed cell death and various plant developmental mechanisms are provided, together with genetic constructs comprising such sequences. Methods for the modulation of the content, structure and metabolism of forestry plants, and particularly for the modulation of PCD and various plant developmental mechanisms in forestry plants, are also disclosed, the methods comprising incorporating one or more of the polynucleotides or genetic constructs of the present invention into the genome of a forestry plant.

Description: COMPOSITIONS AFFECTING PROGRAMMED CELL DEATH AND THEIR USE IN THE MODIFICATION OF FORESTRY PLANT DEVELOPMENT Field of Invention This invention involves the modification of plant developmental responses. Specifically, this invention relates to polynucleotides and polypeptides that affect programmed cell death. These polynucleotides and polypeptides, and genetic constructs comprising such polynucleotides and polypeptides may be used to modulate programmed cell death and thereby alter the developmental cycle of forestry plant cells, hence altering plant development. Background of the Invention Programmed cell death (PCD) refers to an active process, in which gene expression is intimately associated with the events leading to cell death. The plant life cycle contains many instances of such cell death. During plant reproduction and early embryogenesis, events such as organ ablation during unisexual flower development, tapetum degeneration during pollen development and suspensor degeneration during embryo development all involve an active cell death process. During plant morphogenesis and maturation, aleurone cell degradation, the terminal phase of tracheary element differentiation in xylem, leaf blade development in some plants (e.g. genus Monstera), leaf/organ senescence, root cap cell differentiation and the hypersensitive response in plant/pathogen interactions provide further examples of the role of cell death programs in plant developmental cycles. Most of the scientific investigation relating to programmed cell death to date has involved PCD in mammalian cells. PCD in these cells is evidenced by distinct morphological characteristics, such as cytoplasmic condensation, membrane blebbing, DNA fragmentation, condensation and fragmentation of the nucleus, and finally cell corpse engulfment. In mammalian cells, PCD provides a mechanism for removing unwanted cells, as well as for removing pathogens or pathogen-infected cells. It is also believed that a breakdown in normal PCD mechanisms plays an important role in many disease states, including many malignancies. The role of PCD in plant systems has not been studied extensively. Preliminary comparisons between plant and mammalian PCD mechanisms suggest some similarities in the mechanisms. The potential similarities include: an oxygen requirement; activation by hydrogen peroxide; a role for calcium in the activation process; a transcription requirement; a dephosphorylation requirement; proteolytic and nucleolytic enzyme involvement and cell condensation and shrinkage. Modulation of the PCD mechanism in any one or more of these areas may affect plant development. Summary of the Invention Briefly, the present invention provides isolated polypeptides, and the polynucleotides encoding the isolated polypeptides, having activity in PCD pathways and various developmental pathways in forestry plant species. Genetic constructs comprising such polynucleotides and methods for the use of such genetic constructs to modulate PCD and various developmental pathways in forestry plants are also provided. Transgenic cells and plants incorporating such genetic constructs and exhibiting a modified content of the polynucleotides and/or polypeptides of the present invention compared to a wild- type plant, are also provided. Methods for modulating plant cell death, as well as for modulating various forestry plant species developmental pathways, using the polynucleotides and/or polypeptides ofthe present invention, are disclosed. In mammalian PCD, regulation of cell cycle entry appears to be important, and it has been suggested that cell cycle checkpoint regulators may be involved in the commitment of a cell to death. For example, the known tumor suppressor p45 is capable of mediating cell cycle arrest and can trigger PCD. One of the key genes involved in p45 mediated responses is the retinoblastoma gene (RB). This tumor suppressor can bind and inhibit the transcription factors that initiate entry into the cell cycle. In addition, RB plays a regulatory role in the cell death process, depending on its phosphorylation status. The regulation of RB proteolysis by phosphorylation status, and the consequent RB levels in the cells are important in the determination of cellular fates. Two polynucleotides encoding retinoblastoma-related polypeptides (SEQ ID NOS: 36, 37) have been isolated from forestry species. Retinoblastoma-related polypeptides encoded by the polynucleotides are identified as SEQ ID NOS: 80, 81. Another tumor suppressor gene, prohibitin, can also arrest the cell cycle. In rat B lymphocytes, the association of prohibitin with membrane-bound IgM has been suggested as a mediator of PCD in these cells. Furthermore, in yeast, the deletion of prohibitin homologs resulted in a decreased replicative lifespan, leading to successive decreases in cell cycle time, ageing and cellular senescence. While the above studies have been conducted in non-plant systems, it is likely that similar cell cycle modulators are effective in plant systems. Several polynucleotides encoding prohibitin-related polypeptides (SEQ ID NOS: 22-26) have been isolated from forestry species. Prohibitin-related polypeptides encoded by the polynucleotides are identified as SEQ ID NOS: 67-71. Polynucleotides associated with cellular housekeeping functions are necessary for cell health and survival, and their loss may lead to cell death. One such polynucleotide, initially identified in temperature-sensitive mutant hamster cell lines, was DADl (Defender Against Cell Death 1). Cells in temperature-sensitive mutant hamster cell lines undergo PCD at restrictive temperatures, and it has been shown that the Arabidopsis DADl can rescue the hamster temperature-sensitive mutant. The presence of DADl can also reduce cell death in the developing embryo of the worm Caenorhabditis elegans, which undergoes developmentally-regulated cell death. DADl has been shown to be a component of oligosaccharyltransferase, involved in N-linked glycosylation. The induction of cell death by DADl inactivation, as well as the ability of DADl to reduce PCD during development illustrates the essential role of this housekeeping gene. Several polynucleotides encoding DADl -related polypeptides (SEQ ID NOS: 6-9) have been isolated from forestry species. DADl -related polypeptides encoded by the polynucleotides are identified as SEQ ID NOS: 51-54. Another housekeeping polynucleotide which may be used to control cell survival and cell death is the TATA Box Binding Protein (TFIID). TFIID is the most important general factor required for gene transcription by RNA Polymerase II. TFIID binds to the TATA box and participates in the first steps of transcription factor assembly, which is important for the control of gene expression. The ability to developmentally or tissue- specifically knock-out TFIID activity provides a method of specifically inducing cell death. Attempts at TFIID knock-out have not been reported for plants. Polynucleotides encoding TFIID-related transcription initiation factors (SEQ ID NOS: 41, 42) have been isolated from forestry species. TFIID-related transcription initiation factors encoded by the polynucleotides are identified as SEQ ID NOS: 85, 86. Another transcription factor involved in the control of mammalian cell death is pur-alpha. Pur-alpha is a single-stranded DNA binding protein, which has been shown to play a role in both DNA replication and transcriptional regulation. Pur-alpha is able to suppress PCD of mammalian cells by two mechanisms. The first is the transcriptional repression of Fas (CD-95), a receptor which transduces a cell death signal by interaction with its ligand, and the second is the protection of mammalian cells against cell death mediated by p53. Polynucleotides encoding allelic variants of plant pur-alpha have been isolated (SEQ ID NOS: 90-91) from forestry species. The corresponding amino acid sequences of the pur-alpha polypeptides encoded by the polynucleotides are identified as SEQ ID NOS: 141-142. The actual process of cell death involves the degradation of proteins and nucleic acids, mediated by proteases and nucleases. Experimental work done with mammalian systems suggests that proteases may be an important trigger of cell death. In animals, the caspase family of cysteine proteases are major effectors of this process. Cysteine proteases have been identified in plants which are up-regulated and specifically associated with aleurone and tracheary element cell death. Polynucleotides encoding cysteine proteases in forestry species have been identified as SEQ ID NOS: 92-125. The corresponding amino acid sequences of polypeptides encoded by the polynucleotides are identified by SEQ ID NOS: 143-176. In addition, an aspartic nuclease, nucellin, has been shown to be specifically associated with nucellar cell death. Polynucleotides encoding a nucellin-like aspartic protease (SEQ ID NOS: 15-16) have been isolated from forestry species. The corresponding amino acid sequences of the aspartic nuclease encoded by the polynucleotides are identified in SEQ ID NOS: 60-61. In addition to actual protease activity, targeting of proteins for proteolytic degradation via the ubiquitin-proteosome pathway is up-regulated during PCD. Human homologs to the Drosophila SINA (Seven In Absentia) gene are activated during PCD. SINA has been shown to target specific proteins for ubiquitination and degradation in both humans and Drosophila. Polynucleotides encoding SINA-related polypeptides (SEQ ID NOS: 38-40, and 200) have been isolated from forestry species. SINA-related polypeptides encoded by the polynucleotides are identified as SEQ ID NOS: 82-84, and 201. Nuclear DNA cleavage, nuclear fragmentation and RNA degradation are active processes that occur during PCD in animals and plants. Specific plant DNases and RNases have been identified during PCD in plant aleurone cells, tracheary elements, cells undergoing a hypersensitive response to a pathogen, as well as during salt stress-induced cell death. Polynucleotides encoding a plant DNase (SEQ ID NO: 10) and xylogenic RNase (SEQ ID NO: 45) have been isolated from forestry species. The corresponding amino acid sequences of the DNase and RNase encoded by the polynucleotides are identified in SEQ ID NOS: 55 and 89, respectively. In mammalian systems, caspase activation can be inhibited by proteins such as Bcl-2, providing protection against cell death. However, other members of the Bcl-2 family, such as Bax, are antagonistic towards the protective effect of Bcl-2 and promote cell death, due to their ability to interact with Bcl-2 and inhibit its protective ability. A recently discovered gene, BI-1 (Bax Inhibitor- 1), was found to inhibit Bax-induced cell death. This gene is identical to a previously identified human gene identified as TEGT (Testis Enhanced Gene Transcript). Polynucleotides encoding TEGT polypeptides isolated from forestry species are identified as SEQ ID NOS: 43-44. The corresponding amino acid sequences of the TEGT polypeptides encoded by the polynucleotides are identified as SEQ ID NOS:87-88. Another protein involved in inhibition of PCD is BAG-1 (Bcl-2-Associated- athanoGene). a multifunctional protein that blocks apoptosis and interacts with several types of proteins, including Bcl-2 family proteins, the kinase Raf-1, certain tyrosine kinase growth factor receptors, and steroid hormone receptors in mammalian cells. It is identical to a hormone-receptor binding protein RAP46. BAG-1 binds to and potentiates the effect of the anti-apoptotic protein Bcl-2, to make cells more resistant to apoptosis. Human BAG-1 is overexpressed in human leukemias, colon, cervical, breast, prostate and lung cancer cell lines. A polynucleotide encoding a BAG-1 polypeptide isolated from forestry species is identified as SEQ ID NO: 204. The corresponding amino acid sequence of the BAG-1 polypeptide encoded by the polynucleotide is identified as SEQ ID NO: 205. The isolated polynucleotide sequence encoding BAG-1 contains a PROSITE motif for a ubiquitin-like domain that is also present in the human and mouse BAG-1 proteins. Numerous studies of mammalian systems have shown that treatments that induce PCD also cause oxidative stress, suggesting a role for oxidative stress in PCD. This has been confirmed by observations that the addition of ROS (Reactive Oxygen Species) or a depletion of cellular antioxidants can cause PCD. PCD can be associated with ROS induction, and PCD can be blocked by the addition of compounds with antioxidant properties. Reactive oxygen species such as superoxide, the hydroxyl radical and hydrogen peroxide can react with and damage cell macromolecules. Additionally, they may set in motion chain reactions in which free radicals are passed from one molecule to another, resulting in extensive cell damage and toxicity. Plants also exhibit ROS induction during PCD, such as during osmotic stress- mediated death, the hypersensitive response and the terminal stages of tracheary element differentiation. In animal cells, the membrane bound NADPH oxidase complex leads to the generation of superoxide, which is then converted to other ROS. In addition, the small cytosolic protein rac2 is required for activation of the oxidase. When a constitutively active rac2 mutant was inserted into mice, a significant enhancement of PCD occurred compared to wild type mice. Biochemical and immunochemical studies have shown that NADPH oxidase and rac2 are present in plant cells and interact during hypersensitive response PCD. Furthermore, the NADPH oxidase is active during osmotic stress-mediated cell death and during the terminal phase of tracheary element differentiation. The gp 91 NADPH oxidase subunit has been cloned from rice and Arabidopsis. Polynucleotides encoding polypeptides relating to Rac2 (SEQ ID NOS: 28- 35) and the gp 91 NADPH oxidase subunit (SEQ ID NO 192) have been isolated from forestry species. The corresponding predicted amino acid sequences for the Rac2-related polypeptides encoded by the polynucleotides given in SEQ ID NOS: 28 and 30-45 are given in SEQ ID NOS: 73 and 74-79. The corresponding predicted amino acid sequence for the gp 91 NADPH oxidase subunit related polypeptide is given in SEQ ID NO: 196. The role of superoxide compounds in plant cell death was illustrated with the discovery of the lesion simulating cell death (lsdl) mutant in Arabidopsis. In this mutant, superoxide was necessary and sufficient to induce and propagate cell death. Lsdl in wild type plants is believed to serve as a monitor to a superoxide-dependent signal and to act as a negative regulator of a plant cell death pathway. Polynucleotides encoding lsdl- related polypeptides (SEQ ID NOS: 13 and 14) have been isolated from forestry species. Lsdl -related polypeptides encoded by the polynucleotides are identified as SEQ ID NOS: 58 and 59. ATL2 was identified as an Arabidopsis cDNA which was toxic when overexpressed in yeast. The nucleotide sequences of five ATL2 variants isolated from forestry species are given in SEQ ID NOS: 1-5 and the corresponding predicted amino acid sequences in SEQ ID NOS: 46-50. Another gene, 11s 1, identified from a maize mutant, is also required to limit the spread of cell death in a developmental manner in leaves. Polynucleotides encoding lethal leaf spot protein Us 1 -related polypeptides (SEQ ID NOS: 11-12) have been isolated from forestry species. Polypeptides encoded by the polynucleotides are identified as SEQ ID NOS: 56-57. Another plant protein from Arabidopsis (oxy5) has been shown to be a member of the annexin family of proteins and protect bacterial cells from oxidative stress. Oxy5 has also been shown to protect mammalian cells from tumor necrosis factor-induced cell death. The involvement of oxidative stress in the various instances of PCD in plants suggests that oxy5 plays a protective role. The annexin sequences show good homology to oxy5, and hence are expected to provide the same function or similar function. The nucleotide sequences of annexin-like proteins isolated from forestry species are given in SEQ ID NOS: 17-21 and the corresponding predicted amino acid sequences in SEQ ID NOS: 62-66. The most actively investigated example of PCD in plants concerns the hypersensitive response (HR) to pathogens. The HR is found in most responses mediated by disease resistance (R) genes. The HR is invoked by the association of a pathogen avirulence gene product with a receptor. This sets in motion a cascade of events involving ion fluxes, kinase/phosphatase actions and an oxidative burst leading to localized cell death and the induction of systemic acquired resistance (SAR), in which other parts of the plants develop an acquired resistance to the pathogen. A wide range of plant disease receptors have been identified, including polypeptides that span the cell membrane and contain an extracellular and cytoplasmic domain, as well as polypeptides that are strictly cytoplasmic and do not contain an extracellular domain. Of the cytoplasmic polypeptide receptors involved in the HR, three families are of primary interest. The first is the RPS2-like polypeptide family, in which the polypeptides include an amino-terminal leucine zipper region, a nucleotide-binding site, an internal hydrophobic domain and a carboxy-terminal leucine-rich repeat. The second is the RPP5-like polypeptide family, in which the polypeptides include an amino-terminal Tolllike domain, a nucleotide-binding site, an internal hydrophobic domain and a carboxy- terminal leucine-rich repeat region. The nucleotide sequences of RPP5-like proteins isolated from forestry species are given in SEQ ID NOS: 126-140, and the corresponding predicted amino acid sequences in SEQ ID NOS: 177-191. The third family of cytoplasmic receptors involved in the HR is the PTO-like family, in which the polypeptides include a serine-threonine kinase domain. The exact mechanisms by which the HR cell death signals are transduced are not known, although protein-protein interactions and kinase reactions have been shown to be involved in the PTO-like family, with several PTO-interacting protein genes identified. Downstream of the initial avirulence/receptor interaction, the development of SAR occurs, which involves the NPR1 gene. Mutations in the NPR1 gene increase the susceptibility of plants to pathogen infection and prevent the development of HR PCD and SAR. The expression of R genes in transgenic plants has allowed the development of HR PCD and resistance to specific pathogens. In addition, the expression of PTO-like family members, such as Fen, can lead to PCD in the absence of a pathogen. The nucleotide sequences encoding NPRl -like proteins isolated from forestry species are given in SEQ ID NOS: 193-195 and the corresponding predicted amino acid sequences in SEQ ID NOS: 197-199. The nucleotide sequence encoding a Fen-like protein isolated from forestry species is given in SEQ ID NO: 27, and the corresponding predicted amino acid sequence in SEQ ID NO: 72. Little is known about the roles of these genes in other cases of plant PCD. An interesting point comes from the realisation that members of the plant R gene families and NPRl show similarity to several proteins that are involved in animal development and defense. The discovery of a shared pathway linking developmental processes and disease resistance suggests that there may be roles for HR- associated genes in other plant PCD and developmental pathways. In a first aspect, the present invention provides isolated polynucleotide sequences identified in the attached Sequence Listing as SEQ ID NOS: 1-45, 90-140, 192-195, 200, 202 and 206; variants of those sequences; extended sequences comprising the sequences set out in SEQ ID NOS: 1-45, 90-140, 192-195, 200, 202and 206, and their variants; probes and primers corresponding to the sequences set out in SEQ ID NOS: 1-45, 90-140, 192-195, 200, 202 and 206, and their variants; polynucleotides comprising at least a specified number of contiguous residues of any of the polynucleotides identified as SEQ ID NOS: 1-45, 90-140, 192-195, 200, 202 and 206 (x-mers); and extended sequences comprising portions of the sequences set out in SEQ ID NOS: 1-45, 90-140, 192-195, 200, 202 and 206; all of which are referred to herein, collectively, as "polynucleotides of the present invention." The present invention also provides isolated polypeptide sequences identified in the attached Sequence Listing as SEQ ID NOS: 46-89, 141-191, 196-199, 201 and 205; polypeptide variants of those sequences; and polypeptides comprising the isolated polypeptide sequences and variants of those sequences. The polynucleotide sequences identified as SEQ ID NOS: 1-45, 90-140, 192-195, 200, 202 and 206, were derived from forestry plant sources, namely from Eucalyptus grandis and Pinus radiata. Some of the polynucleotides of the present invention are "partial" sequences, in that they do not represent a full length gene encoding a full length polypeptide. Such partial sequences may be extended by analyzing and sequencing various DNA libraries using primers and/or probes and well known hybridization and/or PCR techniques. Partial sequences may be extended until an open reading frame encoding a polypeptide, a full length polynucleotide and/or gene capable of expressing a polypeptide, or another useful portion of the genome is identified. Such extended sequences, including full length polynucleotides and genes, are described as "corresponding to" a sequence identified as one of the sequences of SEQ ID NOS: 1-45, 90-140, 192-195, 200, 202 and 206, or a variant thereof, or a portion of one of the sequences of SEQ ID NOS: 1-45, 90-140, 192-195, 200, 202 and 206, or a variant thereof, when the extended polynucleotide comprises an identified sequence or its variant, or an identified contiguous portion (x-mer) of one of the sequences of SEQ ID NOS: 1- 45, 90-140, 192-195, 200, 202 and 206, or a variant thereof. Similarly, RNA sequences, reverse sequences, complementary sequences, antisense sequences, and the like, corresponding to the polynucleotides of the present invention, may be routinely ascertained and obtained using the cDNA sequences identified as SEQ ID NOS: 1-45, 90- 140, 192-195, 200, 202 and 206. The polynucleotides identified as SEQ ID NOS: 1-45, 90-140, 192-195, 200, 202 and 206, may contain open reading frames ("ORFs") or partial open reading frames encoding polypeptides. Additionally, open reading frames encoding polypeptides may be identified in extended or full length sequences corresponding to the sequences set out as SEQ ID NOS: 1-45, 90-140, 192-195, 200, 202 and 206. Open reading frames may be identified using techniques that are well known in the art. These techniques include, for example, analysis for the location of known start and stop codons, most likely reading frame identification based on codon frequencies, etc. Suitable tools and software for ORF analysis are available, for example, on the Internet at http://www.ncbi.nlm.nih.gov/gorf/gorf.html. Open reading frames and portions of open reading frames may be identified in the polynucleotides of the present invention. Once a partial open reading frame is identified, the polynucleotide may be extended in the area of the partial open reading frame using techniques that are well known in the art until the polynucleotide for the full open reading frame is identified. Thus, open reading frames encoding polypeptides may be identified using the polynucleotides of the present invention. Once open reading frames are identified in the polynucleotides of the present invention, the open reading frames may be isolated and/or synthesized. Expressible genetic constructs comprising the open reading frames and suitable promoters, initiators, terminators, etc., which are well known in the art, may then be constructed. Such genetic constructs may be introduced into a host cell to express the polypeptide encoded by the open reading frame. Suitable host cells may include various prokaryotic and eukaryotic cells, including plant cells, mammalian cells, bacterial cells, algae and the like. Polypeptides encoded by the polynucleotides of the present invention may be expressed and used in various assays to determine their biological activity. Such polypeptides may be used to raise antibodies, to isolate corresponding interacting proteins or other compounds, and to quantitatively determine levels of interacting proteins or other compounds. The present invention also contemplates methods for modulating the polynucleotide and/or polypeptide content and composition of a forestry species, such methods involving stably incorporating into the genome of the organism a genetic construct comprising one or more polynucleotides of the present invention. In one embodiment, the target organism is a forestry species, preferably a woody plant, more preferably a woody plant of the Pinus or Eucalyptus species, and most preferably Eucalyptus grandis or Pinus radiata. In a related aspect, a method for producing a forestry plant having an altered genotype or phenotype is provided, the method comprising transforming a plant cell with a genetic construct of the present invention to provide a transgenic cell, and cultivating the transgenic cell under conditions conducive to regeneration and mature plant growth. Forestry plants having an altered genotype or phenotype as a consequence of modulation of the level or content of a polynucleotide or polypeptide of the present invention compared to a wild-type organism, as well as components (seeds, etc.) of such forestry plants, and the progeny of such forestry plants, are contemplated by and encompassed within the present invention. The isolated polynucleotides of the present invention also have utility in genome mapping, in physical mapping, and in positional cloning of genes. Additionally, the polynucleotide sequences identified as SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206, and their variants, may be used to design oligonucleotide probes and primers. Oligonucleotide probes and primers have sequences that are substantially complementary to the polynucleotide of interest over a certain portion of the polynucleotide. Oligonucleotide probes designed using the polynucleotides of the present invention may be used to detect the presence and examine the expression patterns of genes in any organism having sufficiently similar DNA and RNA sequences in their cells using techniques that are well known in the art, such as slot blot DNA hybridization techniques. Oligonucleotide primers designed using the polynucleotides of the present invention may be used for PCR amplifications. Oligonucleotide probes and primers designed using the polynucleotides of the present invention may also be used in connection with vaπous microarray technologies, including the microarray technology used by Synteni (Palo Alto, California). The polynucleotides of the present invention may also be used to tag or identify an organism or reproductive material therefrom. Such tagging may be accomplished, for example, by stably introducing a non-disruptive non-functional heterologous polynucleotide identifier into an organism, the polynucleotide comprising one of the polynucleotides of the present invention. The polypeptides of the present invention and the polynucleotides encoding the polypeptides have activity in PCD and various developmental pathways in plants. The polynucleotides were putatively identified by DNA and polypeptide similarity searches. In the attached Sequence Listing, SEQ ID NOS. 1-28, 30-45, 90-140, 192-195, 200 and 204, are polynucleotide sequences that encode the polypeptides listed in SEQ ID NOS. 46-73, 74-89, 141-191, 196-199, 201 and 205, respectively. The polynucleotides and polypeptides of the present invention have demonstrated similarity to the following polypeptides that are known to be involved in PCD and/or plant developmental processes: TABLE 1 In one embodiment, isolated polynucleotides of the present invention comprise a sequence selected from the group consisting of: (a) sequences recited in SEQ ID NOS: 1- 45, 90-140, 192-195, 200, 204 and 206; (b) complements of the sequences recited in SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206; (c) reverse complements of the sequences recited in SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206; (d) reverse sequences of the sequences recited in SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206; and (e) sequences having at least 50%, 75%, 90%, or 98% identity, as defined herein, to a sequence of (a) — (d) or a specified region of a sequence of (a) ~ (d). In a further aspect, isolated polypeptides encoded by the polynucleotides of the present invention are provided. In one embodiment, such polypeptides comprise an amino acid sequence recited in SEQ ID NOS: 46-89, 141-191, 196-199, 201 and 205, and variants thereof, as well as polypeptides expressed by polynucleotides of the present invention, including polynucleotides comprising a sequence of SEQ ID NOS: 1-45, 90- 140, 192-195, 200 and 204. In another aspect, the invention provides genetic constructs comprising a polynucleotide of the present invention, either alone, in combination with one or more additional polynucleotides of the present invention, or in combination with one or more known polynucleotides, together with cells and target organisms comprising such constructs. In a related aspect, the present invention provides genetic constructs comprising, in the 5 '-3' direction, a gene promoter sequence, an open reading frame coding for at least a functional portion of a polypeptide encoded by a polynucleotide of the present invention, and a gene termination sequence. The open reading frame may be oriented in either a sense or antisense direction. Genetic constructs comprising a gene promoter sequence, a polynucleotide of the present invention, and a gene termination sequence are also contemplated, as are genetic constructs comprising a gene promoter sequence, an untranslated region of a polynucleotide of the present invention, or a nucleotide sequence complementary to an untranslated region, and a gene termination sequence. The genetic construct may further include a marker for the identification of transformed cells. The gene promoter and termination sequences are preferably functional in a host plant and, most preferably, are those native to the host plant. Promoter and termination sequences that are generally used in the art, such as the Cauliflower Mosaic Virus (CMV) promoter, with or without enhancers such as the Kozak sequence or Omega enhancer, and Agrobacterium tumefaciens nopaline synthase terminator, are useful. Tissue-specific promoters may be employed in order to target expression to one or more desired tissues. In a further aspect, methods for producing forestry plants having a modified content of a polynucleotide or polypeptide of the present invention compared to a native organism are provided. The methods involve transforming a target forestry plant with a genetic construct of the present invention to provide a transgenic cell, and cultivating the transgenic cell under conditions conducive to regeneration and mature plant growth. Cells comprising the genetic constructs of the present invention are provided, together with tissues and forestry plants comprising such transgenic cells, and fruits, seeds and other products, derivatives, or progeny of such forestry plants. In yet another aspect of the present invention, methods for modulating PCD, and for modulating various developmental pathways of forestry plants are provided, such methods including stably incorporating into the genome of a forestry plant a genetic construct of the present invention. More specifically, methods for modulating developmental pathways, including wood development, senescence and reproductive development, as well as methods for modulating stress responses in forestry plants, are provided. Preferred forestry plants include woody plants, preferably selected from the group consisting of eucalyptus, pine, acacia, poplar, sweetgum, teak and mahogany species, more preferably from the group consisting of pine and eucalyptus species, and most preferably from the group consisting of Eucalyptus grandis and Pinus radiata. The above-mentioned and additional features of the present invention and the manner of obtaining them will become apparent, and the invention will be best understood by reference to the following more detailed description. Brief Description of the Drawings Fig. 1 shows a Southern blot analysis of tobacco plants transformed with an antisense sequence of a Pinus radiata DADl gene (SEQ ID NO: 8). Fig. 2 shows a Northern blot analysis of tobacco plants transformed with an antisense sequence of Pinus radiata DADl gene (SEQ ID NO: 8). Fig. 3 illustrates detection of a Pinus unique sequence identifier in transformed tobacco plants. Lanes A and B show the hybridization of a probe from SEQ ID NO: 202 to the genomic DNA of tobacco plants which lack the Pinus unique sequence identifier (empty-vector transformed control plants or wild type). Lanes C-E show the hybridization of the probe to the genomic DNA of tobacco plants containing one to three copies ofthe Pinus unique sequence identifier. Figure 4 illustrates detection of a Eucalyptus unique sequence identifier in transformed tobacco plants. Lanes A and B show the hybridization of a probe from SEQ ID NO: 203 to the genomic DNA of tobacco plants which lack the Eucalyptus unique sequence identifier (empty-vector transformed control plants or wild type). Lanes C-E show the hybridization of the probe to the genomic DNA of tobacco plants containing one to two copies of the Eucalyptus unique sequence identifier. Description of Preferred Embodiments Using the methods and materials of the present invention, PCD and/or specific developmental pathways may be modulated in a forestry plant by modifying the polynucleotide and/or polypeptide content of the target organism, for example, by incorporating sense or antisense copies of polynucleotides of the present invention that encode polypeptides involved in the PCD and/or specific developmental pathways into the genome of the forestry plant. In addition, the number of copies and combination of polynucleotides of the present invention may be manipulated in a forestry plant to modify the relative amounts of polypeptides synthesized, thereby producing biological materials having an altered composition and/or developmental metabolism. According to one embodiment, the present invention provides isolated polynucleotides encoding, or partially encoding, polypeptides involved in PCD and/or specific developmental pathways in forestry plants. The polynucleotides of the present invention were isolated from eucalyptus and pine species, but they may alternatively be synthesized using conventional synthesis techniques. Specifically, isolated polynucleotides of the present invention include polynucleotides comprising a sequence selected from the group consisting of sequences identified as SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206; complements of the sequences identified as SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206; reverse sequences of the sequences identified as SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206; reverse complements of the sequences identified as SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206; at least a specified number of contiguous residues (x-mers) of any of the above-mentioned polynucleotides; antisense sequences corresponding to any of the above polynucleotides; and variants of any of the above polynucleotides, as that term is described in this specification. The isolated polynucleotides recited in SEQ ID NOS: 1-45, 90-140, 192-195, 200, and 204, encode, or partially encode, polypeptides recited in SEQ ID NOS: 46-89, 141- 191, 196-199, 201 and 205, respectively, that are involved in PCD and/or developmental processes, as identified in Table 1 above. Using methods and materials of the present invention, the polynucleotide and/or polypeptide content of a target organism, such as a forestry plant, may be increased or reduced, thereby modulating PCD in the organism or in a tissue of the organism, or modulating a developmental pathway in the organism or a tissue by incorporating various polynucleotides of the present invention, including untranslated portions of such polynucleotides and antisense copies of such polynucleotides. In another embodiment, the present invention provides isolated polypeptides encoded by the DNA sequences of SEQ ID NOS: 1-45, 90-140, 192-195, 200and 204. The predicted amino acid sequences corresponding to the polynucleotides set out in SEQ ID NOS: 1-28, 30-45, 90-140, 192-195, 200 and 204, based on the information available at the time of filing this application, are provided in SEQ ID NOS: 46-73, 74-89, 141- 191, 196-199, 201 and 205, respectively. The term "polynucleotide(s)," as used herein, means a single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases and includes DNA and corresponding RNA molecules, including HnRNA and mR A molecules, both sense and antisense strands, and comprehends cDNA, genomic DNA and recombinant DNA, as well as wholly or partially synthesized polynucleotides. An HnRNA molecule contains introns and corresponds to a DNA molecule in a generally one-to-one manner. An mRNA molecule corresponds to an HnRNA and DNA molecule from which the introns have been excised. A polynucleotide may consist of an entire gene, or any portion thereof. A gene is a DNA sequence that codes for a functional protein or RNA molecule. Operable antisense polynucleotides may comprise a fragment of the corresponding polynucleotide, and the definition of "polynucleotide" therefore includes all such operable antisense fragments. Antisense polynucleotides and techniques involving antisense polynucleotides are well known in the art and are described, for example, in Robinson-Benion, et al., "Antisense techniques," Methods in Enzymol. 254(23): 363-375 (1995); and Kawasaki, et al., Artific. Organs 20(8):836-848 (1996). Polynucleotides of the present invention also encompass polynucleotide sequences that differ from the disclosed sequences but which, as a result of the degeneracy of the genetic code, encode a polypeptide which is the same as that encoded by a DNA sequence disclosed herein. The definitions of the terms "complement", "reverse complement" and "reverse sequence", as used herein, are best illustrated by the following examples. For the sequence 5' AGGACC 3', the complement, reverse complement and reverse sequences are as follows: complement 3' TCCTGG 5' reverse complement 3 ' GGTCCT 5 ' reverse sequence 5' CCAGGA 3'. Identification of genomic DNA and heterologous species DNAs can be accomplished by standard DNA/DNA hybridization techniques, under appropriately stringent conditions, using all or part of a cDNA sequence as a probe to screen an appropriate library. Alternatively, PCR techniques using oligonucleotide primers that are designed based on known genomic DNA, cDNA and protein sequences can be used to amplify and identify genomic and cDNA sequences. Synthetic DNA corresponding to the identified sequences and variants may be produced by conventional synthesis methods. All of the polynucleotides described herein are isolated and purified, as those terms are commonly used in the art. In another aspect, the present invention provides isolated polypeptides encoded, or partially encoded, by the above polynucleotides. As used herein, the term "polypeptide" encompasses amino acid chains of any length, including full length proteins, wherein the amino acid residues are linked by covalent peptide bonds. The term "polypeptide encoded by a polynucleotide" as used herein, includes polypeptides encoded by a polynucleotide which comprises an isolated DNA sequence or variant provided herein. In specific embodiments, the inventive polypeptides comprise an amino acid sequence selected from the group consisting of sequences provided in SEQ ID NOS: 46-89, 141-191, 196-199, 201 and 205, as well as variants of such sequences. Polypeptides of the present invention may be produced recombinantly by inserting a DNA sequence that encodes the polypeptide into an expression vector and expressing the polypeptide in an appropriate host. Any of a variety of expression vectors known to those of ordinary skill in the art may be employed. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are E. coli, insect, yeast or a mammalian cell line such as COS or CHO. The DNA sequences expressed in this manner may encode naturally occurring polypeptides, portions of naturally occurring polypeptides, or other variants thereof. In a related aspect, polypeptides are provided that comprise at least a functional portion of a polypeptide having an amino acid sequence selected from the group consisting of sequences provided in SEQ ID NOS: 46-89, 141-191, 196-199, 201 and 205, and variants thereof. As used herein, the "functional portion" of a polypeptide is that portion which contains the active site essential for affecting the function of the polypeptide, for example, the portion of the molecule that is capable of binding one or more reactants. The active site may be made up of separate portions present on one or more polypeptide chains and will generally exhibit high binding affinity. Functional portions of a polypeptide may be identified by first preparing fragments of the polypeptide by either chemical or enzymatic digestion of the polypeptide, or by mutation analysis of the polynucleotide that encodes the polypeptide and subsequent expression of the resulting mutant polypeptides. The polypeptide fragments or mutant polypeptides are then tested to determine which portions retain biological activity, using, for example, the representative assays provided below. A functional portion comprising an active site may be made up of separate portions present on one or more polypeptide chains and generally exhibits high substrate specificity. The term "polypeptide encoded by a polynucleotide" as used herein, includes polypeptides encoded by a polynucleotide comprising a partial isolated polynucleotide of the present invention. Portions and other variants of the inventive polypeptides may also be generated by synthetic or recombinant means. Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may be generated using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, J. Am. Chem. Soc. 85: 2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer / Applied Biosystems, Inc. (Foster City, California), and may be operated according to the manufacturer's instructions. Variants of a native polypeptide may be prepared using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagensis (Kunkel, T., Proc. Natl. Acad. Sci. USA 82: 488-492, 1985). Sections of DNA sequences may also be removed using standard techniques to permit preparation of truncated polypeptides. In general, the polypeptides disclosed herein are prepared in an isolated, substantially pure form. Preferably, the polypeptides are at least about 80% pure; more preferably at least about 90% pure; and most preferably, at least about 99% pure. In certain preferred embodiments, described in detail below, the isolated polypeptides are incorporated into pharmaceutical compositions or vaccines for use in the treatment of skin disorders. As used herein, the term "variant" comprehends nucleotide or amino acid sequences different from the specifically identified sequences, wherein one or more nucleotides or amino acid residues is deleted, substituted, or added. Variants may be naturally occurring allelic variants, or non-naturally occurring variants. Variant sequences (polynucleotide or polypeptide) preferably exhibit at least 50%; more preferably, at least 75%; and most preferably, at least 90% identity to a sequence of the present invention. The percentage identity is determined by aligning the two sequences to be compared as described below, determining the number of identical residues in the aligned portion, dividing that number by the total number of residues in the inventive (queried) sequence, and multiplying the result by 100. Polynucleotide and polypeptide sequences may be aligned, and percentage of identical nucleotides in a specified region may be determined against another polynucleotide, using computer algorithms that are publicly available. Two exemplary algorithms for aligning and identifying the similarity of polynucleotide sequences are the BLASTN and FASTA algorithms. Polynucleotides may also be analyzed using the BLASTX algorithm, which compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database. The similarity of polypeptide sequences may be examined using the BLASTP algorithm. The BLASTN, BLASTX and BLASTP programs are available on the NCBI anonymous FTP server (ftp://ncbi.nlm.nih.gov) under /blast/executables/. The BLASTN algorithm version 2.0.4 [Feb-24-1998 and version 2.0.6 [Sep-16-1998[, set to the default parameters described in the documentation and distributed with the algorithm, are preferred for use in the determination of polynucleotide variants according to the present invention. The BLASTP algorithm, set to the default parameters described in the documentation and distributed with the program, is preferred for use in the determination of polypeptide variants according to the present invention. The use of the BLAST family of algorithms, including BLASTN, BLASTP, and BLASTX, is described at NCBFs website at URL http://www.ncbi.nlm.nih.gov/BLAST/newblast.html and in the publication of Altschul, Stephen F., et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," Nucleic Acids Res. 25: 3389-3402, 1997. The computer algorithm FASTA is available on the Internet at the ftp site ftp://ftp.vir ginia.edu/pub/fasta/. Version 2.0u4, February 1996, set to the default parameters described in the documentation and distributed with the algorithm, may be used in the determination of variants according to the present invention. The use of the FASTA algorithm is described in Pearson, WR and Lipman, DJ, "Improved Tools for Biological Sequence Analysis," Proc. Natl. Acad. Sci. USA 85: 2444-2448, 1988; and W.R. Pearson, "Rapid and Sensitive Sequence Comparison with FASTP and FASTA," Methods in Enzymology 183: 63-98, 1990. The following running parameters are preferred for determination of alignments and similarities using BLASTN that contribute to the E values and percentage identity for polynucleotide sequences: Unix running command: blastall -p blastn -d embldb -e 10 -GO -E0 -r 1 -v 30 -b 30 -i queryseq -o results; the parameters are: -p Program Name [String]; -d Database [String]; -e Expectation value (E) [Real]; -G Cost to open a gap (zero invokes default behavior) [Integer]; -E Cost to extend a gap (zero invokes default behavior) [Integer]; -r Reward for a nucleotide match (blastn only) [Integer]; -v Number of one-line descriptions (V) [Integer]; -b Number of alignments to show (B) [Integer]; -i Query File [File In]; and -o BLAST report Output File [File Out] Optional. The following running parameters are preferred for determination of alignments and similarities using BLASTP that contribute to the E values and percentage identity of polypeptide sequences: blastall -p blastp -d swissprotdb -e 10 -G 0 -E 0 -v 30 -b 30 -i queryseq -o results; the parameters are: -p Program Name [String]; -d Database [String]; -e Expectation value (E) [Real]; -G Cost to open a gap (zero invokes default behavior) [Integer]; -E Cost to extend a gap (zero invokes default behavior) [Integer]; -v Number of one-line descriptions (v) [Integer]; -b Number of alignments to show (b) [Integer]; -I Query File [File In]; -o BLAST report Output File [File Out] Optional. The "hits" to one or more database sequences by a queried sequence produced by BLASTN, FASTA, BLASTP or a similar algorithm, align and identify similar portions of sequences. The hits are arranged in order of the degree of similarity and the length of sequence overlap. Hits to a database sequence generally represent an overlap over only a fraction of the sequence length of the queried sequence. The BLASTN, FASTA, and BLASTP algorithms also produce "Expect" values for alignments. The Expect value (E) indicates the number of hits one can "expect" to see over a certain number of contiguous sequences by chance when searching a database of a certain size. The Expect value is used as a significance threshold for determining whether the hit to a database, such as the preferred EMBL database, indicates true similarity. For example, an E value of 0.1 assigned to a polynucleotide hit is interpreted as meaning that in a database of the size of the EMBL database, one might expect to see 0.1 matches over the aligned portion of the sequence with a similar score simply by chance. By this criterion, the aligned and matched portions of the polynucleotide sequences then have a probability of 90% of being the same. For sequences having an E value of 0.01 or less over aligned and matched portions, the probability of finding a match by chance in the EMBL database is 1% or less using the BLASTN or FASTA algorithm. According to one embodiment, "variant" polynucleotides and polypeptides, with reference to each of the polynucleotides and polypeptides of the present invention, preferably comprise sequences having the same number or fewer nucleic or amino acids than each of the polynucleotides or polypeptides of the present invention and producing an E value of 0.01 or less when compared to the polynucleotide or polypeptide of the present invention. That is, a variant polynucleotide or polypeptide is any sequence that has at least a 99% probability of being the same as the polynucleotide or polypeptide of the present invention, measured as having an E value of 0.01 or less using the BLASTN, FASTA, or BLASTP algorithms set at parameters described above. According to a preferred embodiment, a variant polynucleotide is a sequence having the same number or fewer nucleic acids than a polynucleotide of the present invention that has at least a 99% probability of being the same as the polynucleotide of the present invention, measured as having an E value of 0.01 or less using the BLASTN or FASTA algorithms set at parameters described above. Similarly, according to a preferred embodiment, a variant polypeptide is a sequence having the same number or fewer amino acids than a polypeptide of the present invention that has at least a 99%) probability of being the same as a polypeptide of the present invention, measured as having an E value of 0.01 or less using the BLASTP algorithm set at the parameters described above. Alternatively, variant polynucleotides or polypeptides of the present invention comprise a sequence exhibiting at least 50%; more preferably at least 75%; more preferably yet at least 90%; and most preferably at least 98% similarity to a polynucleotide or polypeptide of the present invention, determined as described below. The percentage similarity is determined by aligning sequences using one of the BLASTN, FASTA, or BLASTP algorithms, set at the running parameters described above, and identifying the number of identical nucleic or amino acids over the aligned portions; dividing the number of identical nucleic or amino acids by the total number of nucleic or amino acids of the polynucleotide or polypeptide of the present invention; and then multiplying by 100 to determine the percentage similarity. For example, a polynucleotide of the present invention having 220 nucleic acids has a hit to a polynucleotide sequence in the EMBL database having 520 nucleic acids over a stretch of 23 nucleotides in the alignment produced by the BLASTN algorithm using the parameters described above. The 23 nucleotide hit includes 21 identical nucleotides, one gap and one different nucleotide. The percentage similarity of the polynucleotide of the present invention to the hit in the EMBL library is thus 21/220 times 100, or 9.5%. The polynucleotide sequence in the EMBL database is thus not a variant of a polynucleotide of the present invention. Alternatively, variant polynucleotides of the present invention hybridize to the polynucleotide sequences recited in SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206, or complements, reverse sequences, or reverse complements of those sequences under stringent conditions. As used herein, "stringent conditions" refers to prewashing in a solution of 6X SSC, 0.2% SDS; hybridizing at 65°C, 6X SSC, 0.2% SDS overnight; followed by two washes of 30 minutes each in IX SSC, 0.1% SDS at 65° C and two washes of 30 minutes each in 0.2X SSC, 0.1% SDS at 65°C. The present invention also encompasses polynucleotides that differ from the disclosed sequences but that, as a consequence of the discrepancy of the genetic code, encode a polypeptide having similar enzymatic activity as a polypeptide encoded by a polynucleotide of the present invention. Thus, polynucleotides comprising sequences that differ from the polynucleotide sequences recited in SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206, or complements, reverse sequences, or reverse complements of those sequences as a result of conservative substitutions are contemplated by and encompassed within the present invention. Additionally, polynucleotides comprising sequences that differ from the polynucleotide sequences recited in SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206, or complements, reverse complements, or reverse sequences as a result of deletions and/or insertions totaling less than 10%) of the total sequence length are also contemplated by and encompassed within the present invention. Similarly, polypeptides comprising sequences that differ from the polypeptide sequences recited in SEQ ID NOS: 46-89, 141-191, 196-199, 201 and 205 as a result of amino acid substitutions, insertions, and or deletions totalling less than 10% of the total sequence length are contemplated by an encompassed within the present invention, provided the variant polypeptide has activity in a PCD or plant developmental pathway. The polynucleotides of the present invention may be isolated from various libraries, or may be synthesized using techniques that are well known in the art. The polynucleotides may be synthesized, for example, using automated oligonucleotide synthesizers (e.g., Beckman Oligo 1000M DNA Synthesizer) to obtain polynucleotide segments of up to 50 or more nucleic acids. A plurality of such polynucleotide segments may then be ligated using standard DNA manipulation techniques that are well known in the art of molecular biology. One conventional and exemplary polynucleotide synthesis technique involves synthesis of a single stranded polynucleotide segment having, for example, 80 nucleic acids, and hybridizing that segment to a synthesized complementary 85 nucleic acid segment to produce a 5 nucleotide overhang. The next segment may then be synthesized in a similar fashion, with a 5 nucleotide overhang on the opposite strand. The "sticky" ends ensure proper ligation when the two portions are hybridized. In this way, a complete polynucleotide of the present invention may be synthesized entirely in vitro. Some of the polynucleotides identified as SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206, are referred to as "partial" sequences, in that they do not represent the full coding portion of a gene encoding a naturally occurring polypeptide. The partial polynucleotide sequences disclosed herein may be employed to obtain the corresponding full length genes for various species and organisms by, for example, screening DNA expression libraries using hybridization probes based on the polynucleotides of the present invention, or using PCR amplification with primers based upon the polynucleotides of the present invention. In this way one can, using methods well known in the art, extend a polynucleotide of the present invention upstream and downstream of the corresponding mRNA, as well as identify the corresponding genomic DNA, including the promoter and enhancer regions, of the complete gene. The present invention thus comprehends isolated polynucleotides comprising a sequence identified in SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206, or a variant of one of the specified sequences, that encode a functional polypeptide, including full length genes. Such extended polynucleotides may have a length of from about 50 to about 4,000 nucleic acids or base pairs, and preferably have a length of less than about 4,000 nucleic acids or base pairs, more preferably yet a length of less than about 3,000 nucleic acids or base pairs, more preferably yet a length of less than about 2,000 nucleic acids or base pairs. Under some circumstances, extended polynucleotides of the present invention may have a length of less than about 1,800 nucleic acids or base pairs, preferably less than about 1,600 nucleic acids or base pairs, more preferably less than about 1,400 nucleic acids or base pairs, more preferably yet less than about 1 ,200 nucleic acids or base pairs, and most preferably less than about 1,000 nucleic acids or base pairs. Polynucleotides of the present invention also comprehend polynucleotides comprising at least a specified number of contiguous residues (x-mers) of any of the polynucleotides identified as SEQ ID NO: 1-45, 90-140, 192-195, 200, 204 and 206, complements, reverse sequences, and reverse complements of such sequences, and their variants. Similarly, polypeptides of the present invention comprehend polypeptides comprising at least a specified number of contiguous residues (x-mers) of any of the polypeptides identified as SEQ ID NOS: 46-89, 141-191, 196-199, 201, and 205, and their variants. As used herein, the term "x-mer," with reference to a specific value of "x," refers to a sequence comprising at least a specified number ("x") of contiguous residues of any of the polynucleotides identified as SEQ ID NO: 1-45, 90-140, 192-195, 200, 204 and 206, or the polypeptides identified as SEQ ID NOS: 46-89, 141-191, 196-199, 201 and 205. According to preferred embodiments, the value of x is preferably at least 20; more preferably, at least 40; more preferably yet, at least 60; and most preferably, at least 80. Thus, polynucleotides and polypeptides of the present invention comprise a 20-mer, a 40-mer, a 60-mer, an 80-mer, a 100-mer, a 120-mer, a 150-mer, a 180-mer, a 220-mer, a 250-mer, or a 300-mer, 400-mer, 500-mer or 600-mer of a polynucleotide or polypeptide identified as SEQ ID NOS: 1-201, and 204-206, and variants thereof. Polynucleotide probes and primers complementary to and/or corresponding to SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206, and variants of those sequences, are also comprehended by the present invention. Such oligonucleotide probes and primers are substantially complementary to the polynucleotide of interest. As used herein, the term "oligonucleotide" refers to a relatively short segment of a polynucleotide sequence, generally comprising between 6 and 60 nucleotides, and comprehends both probes for use in hybridization assays and primers for use in the amplification of DNA by polymerase chain reaction. An oligonucleotide probe or primer is described as "corresponding to" a polynucleotide of the present invention, including one of the sequences set out as SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206, or a variant, if the oligonucleotide probe or primer, or its complement, is contained within one of the sequences set out as SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206, or a variant of one of the specified sequences. Two single stranded sequences are said to be substantially complementary when the nucleotides of one strand, optimally aligned and compared, with the appropriate nucleotide insertions and/or deletions, pair with at least 80%, preferably at least 90% to 95%, and more preferably at least 98% to 100%o, of the nucleotides of the other strand. Alternatively, substantial complementarity exists when a first DNA strand will selectively hybridize to a second DNA strand under stringent hybridization conditions. Stringent hybridization conditions for determining complementarity include salt conditions of less than about 1 M, more usually less than about 500 mM, and preferably less than about 200 mM. Hybridization temperatures can be as low as 5° C, but are generally greater than about 22° C, more preferably greater than about 30° C, and most preferably greater than about 37° C. Longer DNA fragments may require higher hybridization temperatures for specific hybridization. Since the stringency of hybridization may be affected by other factors such as probe composition, presence of organic solvents and extent of base mismatching, the combination of parameters is more important than the absolute measure of any one alone. The DNA from plants or samples or products containing plant material can be either genomic DNA or DNA derived by preparing cDNA from the RNA present in the sample. In addition to DNA-DNA hybridization, DNA-RNA or RNA-RNA hybridization assays are also possible. In the first case, the mRNA from expressed genes would then be detected instead of genomic DNA or cDNA derived from mRNA of the sample. In the second case, RNA probes could be used. In addition, artificial analogs of DNA hybridizing specifically to target sequences could also be used. In specific embodiments, the oligonucleotide probes and/or primers comprise at least about 6 contiguous residues, more preferably at least about 10 contiguous residues, and most preferably at least about 20 contiguous residues complementary to a polynucleotide sequence of the present invention. Probes and primers of the present invention may be from about 8 to 100 base pairs in length or, preferably from about 10 to 50 base pairs in length or, more preferably from about 15 to 40 base pairs in length. The probes can be easily selected using procedures well known in the art, taking into account DNA-DNA hybridization stringencies, annealing and melting temperatures, and potential for formation of loops and other factors, which are well known in the art. Tools and software suitable for designing probes, and especially suitable for designing PCR primers, are available on the Internet, for example, at URL http://www.horizonpress.com/pcr/. Preferred techniques for designing PCR primers are also disclosed in Dieffenbach, CW and Dyksler, GS, PCR Primer: a laboratory manual, CSHL Press: Cold Spring Harbor, NY, 1995. A plurality of oligonucleotide probes or primers corresponding to a polynucleotide of the present invention may be provided in a kit form. Such kits generally comprise multiple DNA or oligonucleotide probes, each probe being specific for a polynucleotide sequence. Kits of the present invention may comprise one or more probes or primers corresponding to a polynucleotide of the present invention, including a polynucleotide sequence identified in SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206. In one embodiment useful for high-throughput assays, the oligonucleotide probe kits of the present invention comprise multiple probes in an array format, wherein each probe is immobilized at a predefined, spatially addressable location on the surface of a solid substrate. Array formats which may be usefully employed in the present invention are disclosed, for example, in U.S. Patents No. 5,412,087, 5,545,451, and PCT Publication No. WO 95/00450, the disclosures of which are hereby incorporated by reference. Probes, preferably in the form of an array, may be employed to screen for differences in organisms or samples or products containing genetic material using high- throughput screening techniques that are well known in the art. The significance of using probes in high-throughput screening systems is apparent for applications such as plant breeding and quality control operations in which there is a need to identify large numbers of seed lots and plant seedlings, to examine samples or products for unwanted plant materials, to identify plants or samples or products containing plant material for quarantine purposes, etc., or to ascertain the true origin of plants or samples or products containing plant material. Screening for the presence or absence of polynucleotides of the present invention used as identifiers for tagging plants is valuable for later detecting the amount of gene flow in plant breeding, introgression of genes via dispersed pollen, etc. In this manner, oligonucleotide probe kits of the present invention may be employed to examine the presence/absence (or relative amounts in case of mixtures) of polynucleotides in different samples or products containing different materials rapidly and in a cost-effective manner. Examples of plant species, which may be examined using the present invention include forestry species, such as pine and eucalyptus species, other tree species, and even agricultural and horticultural plants. For applications where modulation of PCD and/or a developmental pathway is desired, an open reading frame may be inserted into a genetic construct in a sense or antisense orientation, such that transformation of a forestry plant with the genetic construct produces a change in the copy number of a polynucleotide or the expression level of a polypeptide compared to the polynucleotide copy number and/or polypeptide expression level in a wild-type organism. Transformation with a genetic construct comprising an open reading frame in a sense orientation will generally result in an increased expression level of the polypeptide encoded by the selected polynucleotide, while transformation with a genetic construct comprising an open reading frame in an antisense orientation will generally result in reduced expression of the polypeptide encoded by the selected polynucleotide. A forestry plant transformed with a genetic construct comprising an open reading frame of the present invention in either a sense or antisense orientation may be screened for increased or reduced copy numbers of the selected polynucleotide, or increased or reduced expression of the polypeptide of interest using techniques well known to those of skill in the art. Plants having the desired alterations may thus be identified and isolated. In general, an increase or reduction in the expression level of a polypeptide of interest of at least 25%, compared to expression levels in a corresponding wild-type organism, are significant. Transformation of a target organism with a genetic construct of the present invention results in a modification in the polypeptide synthesis or content or structure in the target organism, producing a modification from the wild-type plant in the area of PCD or in a developmental pathway. Methods of the present invention involve modulating, generally promoting, and inhibiting, PCD in a forestry species. For example, transformation of a target organism with a genetic construct having an open reading frame coding for a polypeptide encoded by a polynucleotide of the present invention wherein the open reading frame is in a sense orientation and the polypeptide contributes to an increased level of PCD, generally produces a significant increase in the amount or expression of the polypeptide in the target organism and, consequently, a significant increase in PCD. Similarly, transformation of a target organism with a genetic construct having an open reading frame coding for a polypeptide encoded by a polynucleotide of the present invention wherein the open reading frame is in a sense orientation and the polypeptide contributes to a reduced level of PCD, generally produces a significant reduction in the amount or expression of the polypeptide in the target organism and, consequently, a significant reduction in PCD. Transformation of a target organism with a genetic construct comprising an open reading frame in an antisense orientation or an untranslated region of a polynucleotide generally produces a decrease in the level of the corresponding polypeptide, thereby producing a corresponding increase or reduction in PCD, depending on the role of the specific polypeptide. It will be recognized that transformation with other genetic constructs of the present invention will produce changes in the content, composition and/or metabolism of various polypeptides that play a role in PCD and/or plant developmental pathways, thereby producing changes in the content, composition, and/or metabolism of the forestry plant. More specifically, methods of the present invention contemplate selectively promoting PCD in a forestry plant or cell population by: (1) introducing or increasing the copy number of a polynucleotide comprising a sequence selected from the group consisting of the sequences recited in SEQ ID NOS: 1-5, 10, 15, 16, 27-35, 38-40, 45, 92- 140, 192-195, and 200, and variants of such sequences; (2) introducing, or increasing the expression level of, or activating a polypeptide encoded by a polynucleotide comprising a sequence selected from the group of sequences recited in SEQ ID NOS: 1-5, 10, 15, 16, 27-35, 38-40, 45, 92-140, 192-195, and 200, and variants of such sequences; (3) introducing, or increasing the expression level of, or activating a polypeptide comprising a sequence selected from the group consisting of the sequences recited in SEQ ID NOS: 46-50, 55, 60, 61, 72-79, 82-84, 89, 143-191, 196-199, and 201, and variants of such sequences; (4) reducing the copy number of a polynucleotide comprising a sequence selected from the group consisting of the sequences recited in SEQ ID NOS: 6-9, 11-14, 17-26, 36, 37, 41-44, 90, 91 and 204, and variants of such sequences; (5) reducing the expression level of or inactivating a polypeptide encoded by a polynucleotide comprising a sequence selected from the group of sequences recited in SEQ ID NOS: 6-9, 1 1-14, 17-26, 36, 37, 41-44, 90, 91 and 204, and variants of such sequences; or (6) reducing the expression level of or inactivating a polypeptide comprising a sequence selected from the group consisting of the sequences recited in SEQ ID NOS: 51-54, 56-59, 62-71 , 80. 81 , 85-88, 141 , 142, and 205 and variants of such sequences. Methods of the present invention also contemplate selectively inhibiting PCD in a forestry plant or cell population by: (1) introducing or increasing the copy number of a polynucleotide comprising a sequence selected from the group consisting of the sequences recited in SEQ ID NOS: 6-9, 1 1-14, 17-26, 36, 37, 41-44, 90, 91 and 204, and variants of such sequences; (2) introducing, or increasing the expression level of, or activating a polypeptide encoded by a polynucleotide comprising a sequence selected from the group of sequences recited in SEQ ID NOS: 6-9, 1 1-14, 17-26, 36, 37, 41-44, 90, 91 and 204, and variants of such sequences; (3) introducing, or increasing the expression level of, or activating a polypeptide comprising a sequence selected from the group consisting of the sequences recited in SEQ ID NOS: 51-54, 56-59, 62-71 , 80, 81 , 85-88, 141 , 142 and 205, and variants of such sequences; (4) reducing the copy number of a polynucleotide comprising a sequence selected from the group consisting of the sequences recited in SEQ ID NOS: 1 -5, 10, 15, 16, 27-35, 38-40, 45, 92-140, 192-195, and 200, and variants of such sequences; (5) reducing the expression level or inactivating a polypeptide encoded by a polynucleotide comprising a sequence selected from the group of sequences recited in SEQ ID NOS: 1-5, 10, 15, 16, 27-35, 38-40, 4, 92-140, 192- 195, and 200, and variants of such sequences; or (6) reducing the expression level of or inactivating a polypeptide comprising a sequence selected from the group consisting of the sequences recited in SEQ ID NOS: 46-50, 55, 60, 61 , 72-79, 82-84, 90, 143-191 , 196- 199, and 201 , and variants of such sequences. Expression of a polynucleotide involved in PCD or a selected developmental pathway may be inhibited by inserting a portion of an open reading frame of the present invention, in either sense or antisense orientation, in the genetic construct. Such portions need not be full-length but preferably comprise at least 25 and more preferably at least 50 residues of a polynucleotide of the present invention. A much longer portion, or even the full length polynucleotide corresponding to the complete open reading frame, may be employed. The portion of the open reading frame does not need to be precisely the same as the endogenous sequence, provided that there is sufficient sequence similarity to achieve inhibition of the target polynucleotide. Thus a sequence derived from one species may be used to inhibit expression of a polypeptide in a different species. According to another embodiment, the genetic constructs of the present invention comprise a polynucleotide including an untranslated region of a polynucleotide coding for a polypeptide encoded by a polynucleotide of the present invention, or a polynucleotide complementary to such an untranslated region. Examples of untranslated regions that may be usefully employed in such constructs include introns and 5 '-non-coding leader sequences. Transformation of a forestry plant with such a genetic construct generally produces a reduction in the expression level of the polypeptide by the process of cosuppression, in a manner similar to that discussed, for example, by Napoli, et al., Plant Cell 2: 279-290, 1990; and de Carvalho Niebel, et al., Plant Cell 7: 347-358, 1995. Alternatively, regulation may be achieved by inserting appropriate sequences or subsequences (e.g. DNA or RNA) in ribozyme constructs (Mclntyre CL, Manners TM, "Strategies for the suppression of peroxidase gene expression in tobacco: designing efficient ribozymes," Transgenic Res. 5(4): 257-262, 1966). Ribozymes are synthetic RNA molecules that comprise a hybridizing region complementary to two regions, each of which comprises at least 5 contiguous nucleotides in a mRNA molecule encoded by one of the inventive polynucleotides. Ribozymes possess highly specific endonuclease activity, which autocatalytically cleaves the mRNA. The genetic constructs of the present invention may further comprise a gene promoter sequence and a gene termination sequence, operably linked to the polynucleotide and capable of controlling expression of the polypeptide. The gene promoter sequence is generally positioned at the 5' end of a polynucleotide to be transcribed, and is employed to initiate transcription of the polynucleotide. Gene promoter sequences are generally found in the 5' untranslated region of a gene, but they may exist downstream of the open reading frame or in introns (Luehrsen, KR, Mol. Gen. Genet. 225: 81-93, 1991), or in the coding region, as for example in a plant defense gene (Douglas, et a\., EMBO J. 10: 1767-1775, 1991). Numerous gene promoter sequences that may be usefully employed in genetic constructs of the present invention are well known in the art. The gene promoter sequence, and also the gene termination sequence, may be endogenous to the target host or may be exogenous, provided the promoter is functional in the target host. For example, the promoter and termination sequences used when the target organism is a plant, may be from other plant species, plant viruses, bacterial plasmids and the like. In preferred embodiments, the gene promoter and termination sequences are common to those of the polynucleotide being introduced. Factors influencing the choice of promoter include the desired tissue specificity of the construct, and the timing of transcription and translation. For example, constitutive promoters, such as the 35S Cauliflower Mosaic Virus (CaMV 35S) promoter with or without enhancers, such as the Kozak sequence or the Omega enhancer, and Agrobacterium tumefaciens nopaline synthase terminator, may be usefully employed in the present invention. Use of a tissue specific promoter will result in production of the desired sense or antisense RNA only in the tissue of interest. With genetic constructs employing inducible gene promoter sequences, the rate of RNA polymerase binding and initiation can be modulated by external stimuli, such as light, heat, anaerobic stress, alteration in nutrient conditions and the like. Temporally regulated promoters can be employed to effect modulation of the rate of RNA polymerase binding and initiation at a specific time during development of a transformed cell. Preferably, the original promoters from the gene in question, or promoters from a specific tissue-targeted gene in the organism to be transformed, such as eucalyptus or pine are used. Other examples of gene promoters which may be usefully employed in the present invention include mannopine synthase (mas), octopine synthase (ocs) and those reviewed by Chua et al. (Science 244: 174-181, 1989). The gene termination sequence, which is located 3' to the polynucleotide to be transcribed, may come from the same gene as the gene promoter sequence or may be from a different gene. Many gene termination sequences known in the art may be usefully employed in the present invention, such as the 3' end of the Agrobacterium tumefaciens nopaline synthase gene. However, preferred gene terminator sequences are those from the original polynucleotide, or from the target species to be transformed. The genetic constructs of the present invention may also contain a selection marker that is effective in target cells, such as forestry plant cells, to facilitate the detection of transformed cells containing the genetic construct. Such markers, which are well known in the art, typically confer resistance to one or more toxins. One example of such a marker is the NPTII gene, whose expression results in resistance to kanamycin or hygromycin, antibiotics which are usually toxic to plant cells at a moderate concentration (Rogers et al. in Weissbach, A and Weissbach, H, eds., Methods for Plant Molecular Biology, Academic Press: San Diego, CA, 1988). Transformed cells can thus be identified by their ability to grow in media containing the antibiotic in question. Alternatively, the presence of the desired construct in transformed cells can be determined by means of other techniques that are well known in the art, such as Southern and Western blots. Techniques for operatively linking the components of the genetic constructs of the present invention are well known in the art and include the use of synthetic linkers containing one or more restriction endonuclease sites as described, for example, by Sambrook, et al., Molecular Cloning: A Laboratory Manual, CSHL: Cold Spring Harbor, NY, 1989). Genetic constructs of the present invention may be linked to a vector having at least one replication system, for example E. coli, whereby after each manipulation, the resulting construct can be cloned and sequenced, and the correctness of the manipulation determined. The genetic constructs of the present invention are used to transform forestry plants, including gymnosperms (e.g. Scots pine (Aronen, Finnish Forest Res. Papers v.595, 1996), white spruce (Ellis et al., Biotechnology 11 :94-92, 1993), and larch (Huang et al., In Vitro Cell 27:201-207, 1991). In one preferred embodiment, the genetic constructs of the present invention are employed to transform woody plants, herein defined as a perennial tree or shrub whose stem increases in diameter each year by the addition of woody tissue. Preferred forestry plants are selected from the group consisting of eucalyptus and pine species, most preferably from the group consisting of Eucalyptus grandis and Pinus radiata. Other species which may be usefully transformed with the DNA constructs of the present invention include, but are not limited to: pines such as Pinus banksiana, Pinus brutia, Pinus caribaea, Pinus clausa, Pinus contorta, Pinus coulteri, Pinus echinata, Pinus eldarica, Pinus ellioti, Pinus jeffreyi, Pinus lambertiana, Pinus monticola, Pinus nigra, Pinus palustrus, Pinus pinaster, Pinus ponderosa, Pinus resinosa, Pinus rigida, Pinus serotina, Pinus strobus, Pinus sylvestris, Pinus taeda, Pinus virginiana; other gymnosperm such as Abies amabilis, Abies balsamea, Abies concolor, Abies grandis, Abies lasiocarpa, Abies magnifica, Abies procera, Chamaecyparis lawsoniona, Chamaecyparis nootkatensis, Chamaecyparis thyoides, Huniperus virginiana, Larix decidua, Larix laricina, Larix leptolepis, Larix occidentalis, Larix siberica, Libocedrus decurrens, Picea abies, Picea engelmanni, Picea glauca, Picea mariana, Picea pungens, Picea rubens, Picea sitchensis, Pseudotsuga menziesii, Sequoia gigantea, Sequoia sempervirens, Taxodium distichum, Tsuga canadensis, Tsuga heterophylla, Tsuga mertensiana, Thuja occidentalis, Thuja plicata; and Eucalypts such as Eucalyptus alba, Eucalyptus bancroftii, Eucalyptus botyroides, Eucalyptus bridgesiana, Eucalyptus calophylla, Eucalyptus camaldulensis, Eucalyptus citriodora, Eucalyptus cladocalyx, Eucalyptus coccifera, Eucalyptus curtisii, Eucalyptus dalrympleana, Eucalyptus deglupta, Eucalyptus delagatensis, Eucalyptus diversicolor, Eucalyptus dunnii, Eucalyptus βcifolia, Eucalyptus globulus, Eucalyptus gomphocephala, Eucalyptus gunnii, Eucalyptus henryi, Eucalyptus laevopinea, Eucalyptus macarthurii, Eucalyptus macrorhyncha, Eucalyptus maculata, Eucalyptus marginata, Eucalyptus megacarpa, Eucalyptus melliodora, Eucalyptus nicholii, Eucalyptus nitens, Eucalyptus nova-anglica, Eucalyptus obliqua, Eucalyptus obtusiflora, Eucalyptus oreades, Eucalyptus pauciflora, Eucalyptus polybractea, Eucalyptus regnans, Eucalyptus resinifera, Eucalyptus robusta, Eucalyptus rudis, Eucalyptus saligna, Eucalyptus sideroxylon, Eucalyptus stuartiana, Eucalyptus tereticornis, Eucalyptus torelliana, Eucalyptus urnigera, Eucalyptus urophylla, Eucalyptus viminalis, Eucalyptus viridis, Eucalyptus wandoo, Eucalyptus youmanni. Techniques for stably incorporating genetic constructs into the genome of specific target organisms are well known in the art. Techniques that are suitable for transforming plants include Agrobacterium tumefaciens mediated introduction, electroporation, protoplast fusion, injection into reproductive organs, injection into immature embryos, high velocity projectile introduction and the like. The choice of technique will depend upon the target plant to be transformed. For example, dicotyledonous plants and certain monocots and gymnosperms may be transformed by Agrobacterium Ti plasmid technology, as described, for example by Bevan, Nucl. Acid Res. 12:8711-8721, 1984. Targets for the introduction of the genetic constructs of the present invention include tissues, such as leaf tissue, dissociated cells, protoplasts, seeds, embryos, meristematic regions; cotyledons, hypocotyls, and the like. The preferred method for transforming eucalyptus and pine is via Agrobacterium tumefaciens using adventitious shoot induction or somatic embryogenesis. Target cells having non-native genetic constructs incorporated in their genome may be selected by means of a marker, such as the kanamycin resistance marker discussed above. Transgenic cells may then be cultured in an appropriate medium to regenerate whole plants, using techniques that are well known in the art. In the case of protoplasts, the cell wall is allowed to reform under appropriate osmotic conditions. In the case of seeds or embryos, an appropriate germination or callus initiation medium is employed. For explants, an appropriate regeneration medium is used. Regeneration of plants is well established for many species. For a review of regeneration of forest trees see Dunstan et al., "Somatic embryogenesis in woody plants," pp. 471-450 in Thorpe, TA, ed., "In vitro embryogenesis of plants," (Vol. 20 of Current Plant Science and Biotechnology in Agriculture). Specific protocols for the regeneration of spruce are discussed by Roberts et al., "Somatic Embryogenesis of Spruce," pp. 427-449, in Redenbaugh, K, ed., Synseed: applications of synthetic seed to crop improvement, CRC Press, 1993). The resulting transformed plants may be reproduced sexually or asexually, using methods well known in the art, to give successive generations of transgenic plants. As discussed above, the production of RNA in target plant cells may be controlled by the choice of an appropriate promoter sequence, or by selecting the number of functional copies or the site of integration of the polynucleotides incorporated into the genome of the target host. A target host organism may be transformed with more than one genetic constructs of the present invention, thereby modulating the concentration or activity of more than one polypeptide, affecting more than one tissue, or affecting more than one expression time. Similarly, a genetic construct may be assembled containing more than one open reading frame encoded by a polynucleotide of the present invention or more than one untranslated region of a polynucleotide. The polynucleotides of the present inventive may also be employed in combination with other known sequences encoding various polypeptides. Additionally, the polynucleotides of the present invention may be used as non- disruptive tags for marking organisms, particularly plants. Genetic constructs comprising polynucleotides of the present invention may be stably introduced into an organism as heterologous, non-functional, non-disruptive tags. It is then possible to identify the origin or source of the organism at a later date by determining the presence or absence of the tag(s) in a sample of material. Organisms other than plants may also be tagged with the polynucleotides of the present invention, including commercially valuable animals, fish, bacteria and yeasts. Detection of the tag(s) may be accomplished using a variety of conventional techniques, and generally involves the use of nucleic acid probes. Sensitivity in assaying for the presence of probe may be usefully increased by using branched oligonucleotides, as described by Horn, T, Chang, CA, and Urdea, MS, "Chemical synthesis and characterization of branched oligo-deoxyribonucleotides (bDNA) for use as signal amplifiers in nucleic acid quantification assays," Nucleic Acids Research 25(23): 4842- 4849, 1997, enabling detection of as few as 50 DNA molecules in the sample. The following examples are offered by way of illustration and not by way of limitation. Example 1 Isolation and Characterization of cDNA Clones from Pinus radiata and Eucalyptus srandis Pinus radiata and Eucalyptus grandis cDNA libraries were constructed using non- subtracted or subtracted methods and screened as follows. Total RNA was extracted from the plant tissue using the protocol of Chang et al., Plant Molecular Biology Reporter 11 : 113-116, 1993. mRNA was isolated from the total RNA preparation using a Poly(A) Quik mRNA Isolation Kit (Stratagene, La Jolla, California) or Dynal Oligo (dT) 25 Beads (Dynal, Skogen, Norway). Non-subtracted cDNA libraries were constructed from the purified mRNA by reverse transcriptase synthesis followed by insertion of the resulting cDNA clones in Lambda ZAP using a ZAP Express cDNA Synthesis Kit (Stratagene, La Jolla California) or a Superscript Choice System (Gibco BRL Life Technologies, Gaithersburg Maryland), according to the manufacturer's protocol. The resulting cDNAs were packaged using a Gigapack II Packaging Extract (Stratagene) employing 1 μl of sample DNA from the 5 μl ligation mix. Mass excision of the library was done using XL 1 -Blue MRF' cells and XLOLR cells (Stratagene) with ExAssist helper phage (Stratagene). The excised phagemids were diluted with NZY broth (Gibco BRL, Gaithersburg, Maryland) and plated out onto LB-kanamycin agar plates containing X-gal and isopropylthio-beta-galactoside (IPTG). Subtracted Pinus radiata cDNA libraries (developed using early wood xylem [tester DNA] subtracted against late wood xylem [driver DNA] or late wood xylem [tester DNA] subtracted against early wood xylem [driver DNA] were constructed as follows. mRNA isolated using Dynal Beads (see above) was used to generate cDNA using manufacturer's instructions from the Clontech PCR-Select™ cDNA Subtraction Kit (Clontech Laboratories Ine, Palo Alto, California). Both the tester and driver double- stranded cDNA preparations were digested with restriction endonuclease Rsal and then only the digested tester cDNA population used to generate two distinct tester populations each with different adaptors ligated. The first round of hybridization, using both tester cDNA populations and the driver cDNA population combined, was performed to allow for equalization and enrichment of differentially expressed sequences. This was followed by a second round of hybridization to generate the templates for PCR amplification. Using suppression PCR, differentially expressed sequences were favourably amplified exponentially. This resultant population of cDNAs was then used in a second round of PCR amplification to remove background and further enrich for differentially expressed sequences. PCR products were ligated to T-tailed pBluescript II SK+ (constructed according to the method of Khan et al., TIG 10:7, July 1994; or Hadjeb and Berkowitz, Biotechniques , January 1996). Electro-competent XLl-Blue E. coli cells were electroporated with recombinant plasmids and cells plated onto LB-ampicillin plates containing X-gal and IPTG. Colonies containing cDNA inserts were cultured in NZY broth with the appropriate antibiotic and cDNA was purified by means of alkaline lysis and polyethylene glycol (PEG) precipitation. Agarose gel at 1% was used to screen sequencing templates for chromosomal contamination. Dye primer sequences were prepared using a Turbo Catalyst 800 machine (Perkin Elmer / Applied Biosystems Division, Foster City, California) according to the manufacturer's protocol. Polynucleotides for positive clones were obtained using a Perkin Elmer / Applied Biosystems Division Prism 377 sequencer. cDNA clones were sequenced first from the 5' end and, in some cases, also from the 3' end. For some clones, internal sequences were obtained using subcloned fragments, exonuclease III deletions, or by direct sequencing using gene-specific primers designed to identified regions of the gene of interest. Subcloning was performed using standard procedures of restriction mapping and subcloning to pBluescript II SK+ vector (Stratagene) and other standard sequencing vectors. The determined cDNA sequences, including the polynucleotides of the present invention, were compared to and aligned with known sequences in the EMBL database (as updated to end of August, 1998). Specifically, the polynucleotides identified in SEQ ID NOS. 1 - 45, 90-140, 192-195, 200, 202-204 and 206, were compared to polynucleotides in the EMBL database using the BLASTN algorithm version 2.0.4 [Feb- 24-1998] and version 2.0.6 [Sep-16-1998] set to the preferred parameters described above. Specifically, running parameters used for determination of alignments and similarities using BLASTN that contribute to the E values and percentage identity were as follows: Unix running command: blastall -p blastn -d embldb -e 10 -GO -E0 -r 1 -v 30 -b 30 -i queryseq -o results. Multiple alignments of redundant sequences were used to build up reliable consensus sequences. Based on similarity to known sequences from other plant or non-plant species, the isolated polynucleotides of the present invention identified as SEQ ID NOS. 1-45, 90-140, 192-195, 200and 204, were putatively identified as encoding polypeptides having similarity to the polypeptides shown in Table 1, above. The isolated cDNA sequences were compared to sequences in the EMBL DNA database using the computer algorithm BLASTN. The corresponding predicted protein sequences (DNA translated to protein in each of six reading frames) were compared to sequences in the SwissProt database using the computer algorithm BLASTP. Comparisons of DNA sequences provided in SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206, to sequences in the EMBL DNA database (using BLASTN) and amino acid sequences provided in SEQ ID NOS: 46-89, 141-191, 196-199, 201 and 205, to sequences in the SwissProt database (using BLASTP) were made as of March, 1999. Analysis of the amino acid sequences against the EMBL DNA database dynamically translated in all six reading frames (both strands) was conducted using the TBLASTN algorithm. Analysis of six-frame translations of the polynucleotides of SEQ ID NOS: 1- 45, 90-140, 192-195 200, 204 and 206, were also compared to and aligned with the six- frame translations of polynucleotides in the EMBL database using the TBLASTX program. BLASTN Polynucleotide Analysis The cDNA sequences of SEQ ID NOS: 1-7, 10-18, 20-31, 35-40, 43, 44, 90-94, 98-107, 109, 110, 112-118, 120, 121, 123-140, 192-195, 200, 204, and 206, were determined to have less than 50% identity, determined as described above, to sequences in the EMBL database using the computer algorithm BLASTN, as described above. The cDNA sequences of SEQ ID NOS: 8, 9, 33, 34, 41, 42, 96, 108, and 111 were determined to have less than 75% identity, determined as described above, to sequences in the EMBL database using BLASTN, as described above. The cDNA sequences of SEQ ID NOS: 32, 95, 97, 119, and 122, were determined to have less than 90%> identity, determined as described above, to sequences in the EMBL database using BLASTN, as described above. The cDNA sequence of SEQ ID NO: 9 was determined to have less than 98% identity, determined as described above, to sequences in the EMBL database using BLASTN, as described above. BLASTP Amino Acid Analysis The predicted amino acid sequences of SEQ ID NOS: 46, 48-50, 55, 58, 60, 61, 80, 81, 87-89, 141, 142, 144, 156, 157, 160, 161, 173, 174, 177, 179, 180, 182-191, 198 and 205, were determined to have less than 50% identity, determined as described above, to sequences in the SwissProt database using the BLASTP computer algorithm as described above. The predicted amino acid sequences of SEQ ID NOS: 49, 57, 59, 66, 67, 72, 82-84, 143, 145, 149, 150, 152-155, 159, 162-173, 178, 181, 196, 197, 199, and 201, were determined to have less than 75% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTP, as described above. The predicted amino acid sequences of SEQ ID NOS: 51-54, 56, 62-65, 68-71, 73, 74, 79, 146, 147, 151, 158, and 176, were determined to have less than 90% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTP, as described above. The predicted amino acid sequences of SEQ ID NOS: 75, 78, 85, 86, and 148, were determined to have less than 98% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTP, as described above. TBLASTNand TBLASTX Analysis The predicted amino acid sequences of SEQ ID NOS: 46, 47, 49, 50, 58, 60, 61, 80, 83, 87, 89, 141, 157, 160, 161, 174, 175, 177, 179-180, 182-191, and 197-199, were determined to have less than 50%) identity, determined as described above, to predicted amino acids dynamically translated in all six reading frames (both strands of polynucleotides) in the EMBL database. The predicted amino acid sequences of SEQ ID NOS: 48, 55, 57, 59, 66, 67, 69, 71, 72, 81, 82, 88, 142-145, 149, 150, 152, 153, 155, 156, 162-165, 167-172, 176, 178, 181 and 205, were determined to have less than 75% identity, determined as described above, to predicted amino acids dynamically translated in all six reading frames (both strands of polynucleotides) in the EMBL database. The predicted amino acid sequences of SEQ ID NOS: 51, 52, 56, 62-65, 68, 73, 74, 84, 146, 147, 151, 154, 158, 159, 166, 173, and 196, were determined to have less than 90% identity; and the predicted amino acid sequences of SEQ ID NOS: 53, 75, 78, 79, 85, 86, and 148, were determined to have less than 98% identity; all to dynamic translations in all six reading frames of sequences in the EMBL DNA database using the TBLASTN algorithm version 2.0.6 [Sept- 16- 1998] set to the following parameters: Unix running command: blastall -p blastn -d embldb -elO -GO -E0 -v30 -b30 -i queryseq -o results. Finally, the six-frame translations of the polynucleotide sequences of SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206 were compared to and aligned with six- frame translations of polynucleotides in the EMBL database using the TBLASTX program version 2.0.6 [Sept-16-1998] set to the following running parameters: Unix running command: blastall -p blastn -d embldb -e 10 -G 0 -E 0 -v 30 -b 30 -i queryseq - o results. The translations of the polynucleotides of SEQ ID NOS: 1-8, 10, 12-16, 18, 20- 22, 24-27, 31, 34-40, 42-45, 90-140, 192-195, 204, and 206, were determined to have less than 50% identity, determined as described above, to translations of polynucleotides in the EMBL database using the computer algorithm TBLASTX. The translations of the polynucleotides of SEQ ID NOS: 17, 28-30, and 41, were determined to have less than 75%o identity, determined as described above, to translations of polynucleotides in the EMBL database using the computer algorithm TBLASTX. The translations of the polynucleotide sequences of SEQ ID NOS: 11, 19, and 23, were determined to have less than 90%) identity, determined as described above, to translations of polynucleotides in the EMBL database using the computer algorithm TBLASTX. The translations of the polynucleotide sequence of SEQ ID NO: 9 were determined to have less than 98% identity, determined as described above, to translations of polynucleotides in the EMBL database using the computer algorithm TBLASTX. Example 2 Use of a DADl Gene to Modify Tobacco Transformation of tobacco plants with a Pinus radiata DADl gene A genetic construct comprising the antisense nucleotide of a polynucleotide comprising the coding region of DADl (SEQ ID NO: 8) from P. radiata was constructed and inserted into Agrobacterium tumefaciens by direct transformation using published methods (See An G, Ebert PR, Mitra A, Ha SB, "Binary Vectors," in Gelvin SB, Schilperoort RA (eds). Plant Molecular Biology Manual, Kluwer Academic Publishers: Dordrecht, 1988). The nucleotide sequence of the antisense nucleotide is given in SEQ ID NO: 206. General methods for plant transformation are described in Horsch R, Fry J, Hoffman N, Eichholtz N, Rogers S and Fraley R, "A simple and general method for transferring genes into plants," Science 227: 1229-1231, 1985.) The antisense DNA construct was made by PCR amplification of the open reading frame for the cDNA, followed by purification and cloning of the PCR product into pART7 plasmid. The plasmid was then digested with restriction endonuclease Notl and the 35S promoter- Insert-OCS 3'UTR cloned into the pART27 plant expression vector (See Gleave A, "A versatile binary vector system with a T-DΝA organizational structure conducive to efficient integration of cloned DNA into the plant genome," Plant Molecular Biology 20: 1203-1207, 1992). The presence, integrity and orientation of the transgenic construct was verified by restriction digestion and DNA sequencing. Tobacco (Nicotiana tabacum cv. Samsun) leaf sections were transformed with the antisense construct using the method of Horsch et al. (Science 227: 1229-1231, 1985). Multiple independent transformed plant lines were established for the sense construct. Transformed plants containing the appropriate gene construct were verified using Southern blot experiments. Figure 1 illustrates genomic DNA isolated from seven DADl transgenic tobacco lines (lanes 1-7) and from a non-DADl control tobacco plant (lane 8). As can be seen, plants 1-7 contain DNA which hybridizes with the pine DADl sequence (Final wash conditions: lx SSC, 0.1% SDS at 65 °C), while the control tobacco plant does not. This demonstrates that the antisense polynucleotides coπesponding to DADl were successfully transformed into target plants. Total RNA was isolated from each of the seven DADl antisense transformed tobacco plant lines, and from a control (non DADl -containing) tobacco line. The RNA samples were analysed in a Northern blot experiment to determine the level of expression in each line. mRNA was hybridized with a pine DADl probe (Final wash conditions: O.lx SSC, 0.1% SDS at 65 °C). Figure 2 illustrates the presence of the pine DADl antisense mRNA in all seven transgenic tobacco lines (lanes 1 -7), but not in the control tobacco line (lane 8). Example 3 Demonstration of the Presence / Absence of Unique Sequence Identifiers in Plants Transgenic tobacco plants were created using unique identifier sequences which are not found in tobacco. The unique identifier sequences inserted were isolated from Pinus radiata, SEQ ID NO: 202, and Eucalyptus grandis, SEQ ID NO: 203. The unique identifier sequences were inserted into Agrobacterium tumefaciens LBA4301 (provided as a gift by Dr. C. Kado, University of California, Davis, CA) by direct transformation using published methods (See, An G, Ebert PR, Mitra A, Ha SB, "Binary Vectors," in Gelvin SB, Schilperoort RA (eds), Plant Molecular Biology Manual, Kluwer Academic Publishers: Dordrecht, 1988). The presence and integrity of the unique identifier sequences in the Agrobacterium transgenic constructs were verified by restriction digestion and DNA sequencing. Tobacco (Nicotiana tabacum cv. Samsun) leaf sections were transformed using the method of Horsch et al. (Science, 227:1229-1231, 1985). Three independent transformed plant lines were established for each unique sequence identifier used. Two empty-vector control plant lines were established using an empty gene transfer vector that lacked a unique sequence identifier. The uniqueness of the sequence identifiers was assayed using Southern blot analyses to test for the presence of the sequence identifier in the genome of the plants. If the sequence identifier is unique and therefore useful as a tag, then the sequence identifier should be clearly absent in plants which have not been tagged and it should be clearly present in plants which have been tagged. In the present example, the unique identifiers would be expected to be absent in the empty-vector transformed control plants. The unique identifier would be expected to be present in the transgenic plants transformed with the unique sequence identifiers. Genomic DNA was prepared from empty-vector transformed control plants and plants transformed with unique sequence identifiers using the cetyltrimethyl-ammonium bromide (CTAB) extraction method of Murray and Thompson (Nucleic Acids Research 8:4321-4325, 1980). The DNA samples were digested with the restriction enzyme EcøRI in the case of the plants transformed with the Pinus unique sequence identifier (SEQ ID NO: 202) and the restriction enzyme Xbal in the case of the plants transformed with the Eucalyptus unique sequence identifier (SEQ ID NO: 203). The DNA fragments produced in the restriction digests were resolved on a 1% agarose gel. After the agarose gel electrophoresis step, the DNA samples were transferred to Hybond-N+ brand nylon membranes (Amersham Life Science, Little Chalfont, Buckinghamshire, England) using methods established by Southern (J. Mol. Biol. 98: 503-517). The nylon membranes were probed with radioactively-labeled probes for the unique sequence identifiers identified above and washed at high stringency (final wash: 0.5 X salt sodium citrate buffer (SSC) plus 0.1% sodium dodecyl sulfate (SDS), 15 minutes at 65°C). The hybridisation of the probes to complementary sequences in the genomic DNA samples was detected using auto-radiography. The results are shown in Figures 3 and 4. Figure 3 shows the hybridisation pattern detected in the Southern blot analysis using a probe derived from the Pinus sequence identifier (SEQ ID NO: 202). Lanes A-B contain DNA samples from empty-vector transformed control plants and lanes C-E contain DNA from plants transformed with SEQ ID NO: 202. There is no hybridization in lanes A-B indicating that SEQ ID NO: 202 is not present in empty-vector transformed tobacco plants; that is, SEQ ID NO: 202 is a unique tag suitable for unambiguous marking of tobacco plants. There is strong hybridisation in lanes C-E, indicating that the plants which received SEQ ID NO: 202 via transformation have been clearly and unambiguously tagged with the unique sequence contained in SEQ ID NO: 202. Figure 4 shows the hybridization pattern detected in the Southern blot analysis using a probe derived from the Eucalyptus sequence identifier (SEQ ID NO: 203). Lanes A-B contain DNA samples from empty-vector transformed control plants and lanes C-E contain DNA from plants transformed with SEQ ID NO: 203. There is no hybridisation in lanes A-B indicating that SEQ ID NO: 203 is not present in empty- vector transformed tobacco plants; that is, SEQ ID NO: 203 is a unique tag suitable for unambiguous marking of tobacco plants. There is strong hybridisation in lanes C-E indicating that the plants which received SEQ ID NO: 203 via transformation have been clearly and unambiguously tagged with the unique sequence contained in SEQ ID NO: 203. The data clearly demonstrates the utility of the sequences disclosed in this specification for the purposes of unambiguously tagging transgenic materials. A unique sequence was selected from a large number of potential tags and shown to be absent in the genome of the organism to be tagged. The tag was inserted into the genome of the organism to be tagged and a well-established DNA detection method was used to clearly detect the unique sequence identifier used as the tag. Because of the sequence-specific detection methods used in the example, a user of the invention disclosed in this specification has both a high likelihood of finding a sequence identifier, among the list which has been disclosed, which will be useful for tagging any given organism and an unequivocal method for demonstrating that a tagged organism could only have acquired a given tag through the deliberate addition of the unique sequence to the genome of the organism to be tagged. If the user of this invention maintains the precise sequence of the tag used in a given organism as a secret, then any disputes as to the origin and history of the organism can be unambiguously resolved using the tag detection techniques demonstrated in the present example. SEQ ID NOS: 1- 206 are set out in the attached Sequence Listing. The codes for nucleotide sequences used in the attached Sequence Listing, including the symbol "n," conform to WIPO Standard ST.25 (1998), Appendix 2, Table 1. All references cited herein, including patent references and non-patent publications, are hereby incorporated by reference in their entireties. While in the foregoing specification, this invention has been described in relation to certain preferred embodiments, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein may be varied considerably without departing from the basic principles ofthe invention.

Claims: Claims: 1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (1) the sequences recited in SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206; (2) complements of the sequences recited in SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206; (3) reverse complements of the sequences recited in SEQ ID NOS: 1-45, 90-140; 192-195, 200, 204 and 206; (4) reverse sequences of the sequences recited in SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206; (5) sequences comprising a nucleotide sequence having at least 50% identity to a compare sequence selected from the nucleotide sequences recited in SEQ ID NOS: 1-7, 10-18, 20-31, 35-40, 43, 44, 90-94, 98- 107, 109, 110, 112-118, 120, 121 , 123-140, 192-195, 200, 204, and 206, the percentage identity determined by aligning the sequence and the compare sequences using the BLASTN algorithm version 2.04 set at the following running parameters: Unix running command: blastall -p blastn -d embldb -e 10 -GO -E0 - r 1 -v 30 -b 30 -i queryseq -o results, identifying the number of identical nucleic acids over aligned portions of the sequence and the compare sequences, dividing the number of identical nucleic acids by the total number of nucleic acids of the compare sequence, and multiplying by 100 to determine the percentage similarity; (6) sequences comprising a nucleotide sequence having at least 75%o identity to a compare sequence selected from the nucleotide sequences recited in SEQ ID NOS: 8, 9, 33, 34, 41, 42, 96, 108, and 11 1, the percentage identity determined as described in (5) above; (7) sequences comprising a nucleotide sequence having at least 90% identity to a compare sequence selected from the nucleotide sequences recited in SEQ ID NOS: 32, 95, 97, 119, and 122, the percentage identity determined as described in (5) above; (8) sequences comprising a nucleotide sequence that hybridizes to a polynucleotide comprising a sequence recited in (1) - (7) above under stringent hybridization conditions; (9) sequences comprising a nucleotide sequence that is a 200-mer of a sequence recited in (1) - (7) above; (10) sequences comprising a nucleotide sequence that is a 100-mer of a sequence recited in (1) - (7) above; and (11) sequences comprising a nucleotide sequence differing from a sequence recited in (1) - (4), above, only by one or more conservative substitutions. 2. A genetic construct comprising at least one polynucleotide described in claim 1. 3. A genetic construct comprising at least two polynucleotides described in claim 1. 4. A transgenic forestry plant cell comprising at least one genetic construct according to claim 2. 5. A genetic construct comprising, in the 5 '-3' direction: (a) a gene promoter sequence; (b) a polynucleotide sequence comprising at least one of the following: (1) a polynucleotide comprising a nucleotide sequence of claim 1 coding for at least a functional portion of a polypeptide having activity in a PCD pathway; and (2) a polynucleotide comprising nucleotide sequence of claim 1 that includes an untranslated region of a polynucleotide encoding a polypeptide having activity in a PCD pathway; and (c) a gene termination sequence. 6. The construct of claim 5, wherein the polynucleotide is in a sense orientation. 7. The construct of claim 5, wherein the polynucleotide is in an antisense orientation. 8. The construct of claim 5, wherein the gene promoter sequence and gene termination sequences are functional in a forestry plant host. 9. A forestry plant cell comprising a construct of claim 5. 10. The forestry plant cell of claim 9, wherein the polynucleotide is in a sense orientation. 11. The forestry plant cell of claim 9, wherein the polynucleotide is in an antisense orientation. 12. A forestry plant comprising a forestry plant cell according to claim 9, and fruit and seeds and progeny thereof. 13. The forestry plant of claim 12, wherein the forestry plant is a woody plant. 14. The forestry plant of claim 13, wherein the plant is selected from the group consisting of eucalyptus and pine species. 15. A method for modulating a PCD pathway in a forestry plant, comprising stably incorporating into the genome of the forestry plant a construct of claim 2. 16. The method of claim 15, wherein the construct incorporated into the genome of the forestry plant provides a PCD pathway that is not present in a native form of the forestry plant. 17. A method for modulating a cell death pathway in a forestry plant, comprising stably incorporating into the genome of the forestry plant a construct of claim 5. 18. A method for producing a forestry plant having an altered cell death pathway, comprising: (a) transforming a plant cell with a construct of claim 2 to provide a transgenic plant cell; and (b) cultivating the transgenic plant cell under conditions conducive to regeneration and mature plant growth. 19. An isolated polypeptide encoded by a polynucleotide of claim 1. 20. A polypeptide of claim 19 having activity in a cell death pathway in a forestry plant. 21. An isolated polypeptide comprising an amino acid sequence expressed from a polynucleotide that hybridizes to a nucleotide sequence set forth as SEQ ID NOS: 1-45, 90-140, 192-195, 200, 204 and 206, under stringent hybridization conditions. 2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (1) the sequences set forth in SEQ ID NOS: 46-89, 141-191, 196-199, 201 and 205; (2) sequences comprising an amino acid sequence having at least 50% identity to a compare sequence selected from the amino acid sequences recited in SEQ ID NOS: 46, 48-50, 55, 58, 60, 61, 80, 81, 87-89, 141, 142, 144, 156, 157, 160, 161, 173, 174, 177, 179, 180, 182-191, 198, and 205; (3) sequences comprising an amino acid sequence having at least 75% identity to a compare sequence selected from the amino acid sequences recited in SEQ ID NOS: 49, 57, 59, 66, 67, 72, 82-84, 143, 145, 149, 150, 152-155, 159, 162-173, 178, 181, 196, 197, 199, and 201; (4) sequences comprising an amino acid sequence having at least 90% identity to a compare sequence selected from the amino acid sequences recited in SEQ ID NOS: 51-54, 56, 62-65, 68-71, 73, 74, 79, 146, 147, 151, 158, and 176; and (5) sequences comprising an amino acid sequence having at least 98%) identity to a compare sequence selected from the amino acid sequences recited in SEQ ID NOS: 75, 78, 85, 86, and 148.

Inventors: FLINN BARRY, LASHAM ANNETTE, FLINN, BARRY, LASHAM, ANNETTE
Applicants: FLETCHER CHALLENGE FORESTS LTD, FLINN BARRY, GENESIS RES & DEV CORP LTD, LASHAM ANNETTE, FLETCHER CHALLENGE FORESTS LIMITED, FLINN, BARRY, GENESIS RESEARCH & DEVELOPMENT CORPORATION LIMITED, LASHAM, ANNETTE
Application year: 2000
Main classification: C12N15
IPC codes: A01H5, C07K14, C12N5, C12N15